Drugs / RWJ-800088
RWJ-800088
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03990519 | Jun 2019 → Feb 2020 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RWJ-800088 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315024 ↗ |
| Known as | GW-395058 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315024 ↗ |
| Known as | JNJ-26366821 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03990519 ↗ |
| Known as | SF-003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315024 ↗ |
| Route | Subcutaneous | “subcutaneously (SC)” NCT03990519 ↗ |